Document is current
Any future updates will be listed below
-
Authors
Bayes-Genis, A.
Butler, J.
Stawowczyk, E.
Turner, M.
Lewis, R. D.
Lloyd, I. T.
Ramirez de Arellano, A.
- License Information
-
More Information
Article History
Received: 3 September 2025
Accepted: 25 March 2026
First Online: 10 April 2026
Declarations
:
: Not applicable.
: Not applicable.
: Early analyses were presented previously at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Europe; Copenhagen, Denmark; November 12–15, 2023.
: ABG has lectured and participated in advisory boards for Abbott, AstraZeneca, Bayer, Boehringer Ingelheim, Medtronic, Roche Diagnostics and Vifor. JB has consulted for Consultant Abbott, Adaptyx, American Regent, Amgen, AskBio, AstraZeneca, Bayer, Boehringer Ingelheim, Boston Scientific, Bristol Myers Squibb, Cardiac Dimension, Cardior, CSL Vifor, CVRx, Cytokinetics, Daxor, Diastol, Edwards, Element Sciences, Faraday, Idorsia, Impulse Dynamics, Imbria, Innolife, Intellia, Inventiva, Levator, Lexicon, Eli Lilly, Mankind, Medtronic, Merck, New Amsterdam, Novartis, NovoNordisk, Pfizer, Pharmacosmos, Pharmain, Prolaio, Pulnovo, Regeneron, Renibus, Reprieve, Roche, Rycarma, Saillent, Salamandra, Salubris, SC Pharma, SQ Innovation, Secretome, Sequanna, Transmural, TekkunLev, Tenex, Tricog, Ultromic, Vera, and Zoll. ARdA is an employee of CSL Vifor at the time of original drafts. ES, MT, RL and IL are employees of Health Economics and Outcomes Research Ltd. Health Economics and Outcomes Research Ltd. received fees from CSL Vifor in relation to this study.
